Hyperglycosylated Mutants of Human Immunodeficiency Virus (HIV) Type 1 Monomeric gp120 as Novel Antigens for HIV Vaccine Design

The ability to induce broadly neutralizing antibodies should be a key component of any forthcoming vaccine against human immunodeficiency virus type 1. One potential vaccine candidate, monomeric gp120, has generally failed to elicit such antibodies. We postulated that gp120 might be a better immunog...

Descrizione completa

Dettagli Bibliografici

Pubblicato in:	J Virol
Autori principali:	Pantophlet, Ralph, Wilson, Ian A., Burton, Dennis R.
Natura:	Artigo
Lingua:	Inglês
Pubblicazione:	American Society for Microbiology (ASM) 2003
Soggetti:	Vaccines and Antiviral Agents
Accesso online:	https://ncbi.nlm.nih.govhttps://pmc.ncbi.nlm.nih.gov/articles/PMC154011/ https://ncbi.nlm.nih.govhttps://pubmed.ncbi.nlm.nih.gov/12719582/ https://ncbi.nlm.nih.govhttps://doi.org/10.1128/JVI.77.10.5889-5901.2003
Tags:	Aggiungi Tag Nessun Tag, puoi essere il primo ad aggiungerne!!